Jump to ContentJump to Main Navigation
OOL Systemic Treatment of Prostate Cancer

Edited by Alan Horwich

Publisher:
Oxford University Press
Print Publication Date:
Feb 2010
Print ISBN-13:
9780199561421
Published to Oxford Medicine:
May 2011
DOI:
10.1093/med/9780199561421.001.0001

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Symbols and abbreviations

  • AA

    Anti-androgen

  • ADT

    Androgen deprivation therapy

  • AR

    Androgen receptor

  • ASCO

    American Society of Clinical Oncology

  • BCR

    Biochemical recurrence

  • BFGF

    Basic fibroblast growth factors

  • CAB

    Combined androgen blockade

  • CML

    Chronic myeloid leukemia

  • CPA

    Cyproterone acetate

  • CRPC

    Castration-resistant prostate cancer

  • CSDX

    Casodex®

  • CTC

    Circulating tumor cell

  • DES

    Diethylstilbestrol

  • DHT

    5(-dihydrotestosterone

  • EDTMP

    Ethylenediaminetetramethylene phosphonic aci

  • EGF

    Epidermal growth factor

  • EMP

    Estramustine phosphate

  • EPCP

    Early Prostate Cancer Programme

  • EORTC

    European Organisation for Research and Treatment of Cance

  • ERBT

    External beam radiotherap

  • FDA

    Food and Drug Administratio

  • GnRH

    Gonadotropin-releasing hormon

  • HEDP

    Hydroxyethylene diphosphonat

  • HPG

    Hypothalamic-pituitary-gonadal

  • HSP

    Heat shock proteins

  • IGF-I

    Insulin-like growth factor-

  • IL-6

    Interleukin-6

  • KGF

    Keratinocyte growth factor

  • LH

    Luteinizing hormone

  • LHRH

    Luteinizing hormone releasing hormone

  • MAPK

    Mitogen activated protein kinase

  • MRC

    Medical Research Council

  • NICE

    National Institute for Health and Clinical Excellenc

  • PCTCG

    Prostate Cancer Trialists’ Collaborative Grou

  • PCWG

    Prostate Cancer Working Grou

  • PDGF

    Platelet derived growth factors

  • PKA

    Protein kinase A

  • PKC

    Protein kinase C

  • PPI

    present pain intensity

  • PSA

    Prostate specific antigen

  • PSADT

    PSA doubling tim

  • SPARC

    Satraplatin and Prednisone Against Refractory Cancer

  • SRE

    Skeletal related event

  • SSRI

    Selective serotonin reuptake inhibitors

  • SWOG

    Southwest Oncology Group

  • VEGF

    Vascular endothelial growth factor